Aeolus Pharmaceuticl (AOLS) 0.1900 $AOLS Aeolus
Post# of 273254
Posted On: 09/22/2016 1:10:22 AM
Aeolus Pharmaceuticl (AOLS) 0.1900 $AOLS
Aeolus Pharmaceuticals to Present at Aegis Growth Conference on September 22, 2016
Marketwired - Wed Aug 31, 8:09AM CDT
MISSION VIEJO, CA--(Marketwired - August 31, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today that it will be presenting at the 2016 Aegis Growth Conference on Thursday, September 22nd at 9:00AM PDT / 12 Noon EDT at the Encore at Wynn in Las Vegas. David C. Cavalier, Chairman and Chief Financial Officer will be giving the presentation and meeting with investors.
Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results
Marketwired - Mon Aug 15, 3:29PM CDT
MISSION VIEJO, CA--(Marketwired - August 15, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today financial results for the nine months ended June 30, 2016.
Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference
Marketwire Canada - Mon May 23, 7:01AM CDT
MISSION VIEJO, CA--(Marketwired - May 23, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it will be presenting at the 6th annual LD Micro Invitational on Tuesday, June 7th at 9:00AM PDT / 12 Noon EDT at the Luxe Sunset Boulevard Hotel in Los Angeles. David C. Cavalier, Chairman and Chief Financial Officer will be giving the presentation and meeting with investors.
CORRECTION - Aeolus Announces Second Quarter Fiscal Year 2016 Financial Results and Investor Update Call
Marketwire Canada - Mon May 16, 7:43AM CDT
MISSION VIEJO, CA --(Marketwired - May 16, 2016) - In the news release issued earlier today by Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), we are advised by the company that the headline of the release should read "Aeolus Announces Second Quarter Fiscal Year 2016 Financial Results and Investor Update Call" rather than "Aeolus Announces First Quarter Fiscal Year 2016 Financial Results and Investor Update Call" as originally issued. Complete corrected text follows.
Aeolus Announces First Quarter Fiscal Year 2016 Financial Results and Investor Update Call
Marketwire Canada - Mon May 16, 7:02AM CDT
MISSION VIEJO, CA--(Marketwired - May 16, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today financial results for the three months ended March 31, 2016. The Company also announced a conference call to update investors on its development programs, including its partnership with the Biomedical Advanced Research and Development Authority ("BARDA"
for the development of AEOL-10150 ("10150" as treatment for the pulmonary and delayed effects of acute radiation exposure ("Lung-ARS" .
European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114
Marketwired - Mon Apr 18, 7:02AM CDT
Aeolus Pharmaceuticals (OTCQB: AOLS)
Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 238.41 (-0.26), AVXL: 2.61 (-0.03), ACOR: 27.07 (+0.71), BCLI: 2.42 (-0.10), FOLD: 7.94 (+0.05)
Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malignant Mesothelioma Overview - Therapeutics Development - Pipeline Products for Malignant Mesothelioma - Overview - Pipeline Products for Malignant Mesothelioma - Comparative Analysis - Malignant Mesothelioma - Therapeutics under Development by Companies - Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes - Malignant Mesothelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malignant Mesothelioma - Products under Development by Companies - Malignant Mesothelioma - Products under Investigation by Universities/Institutes - Malignant Mesothelioma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Berg LLC - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Synta Pharmaceuticals Corp. - Targovax AS - TRACON Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2dt2rm/malignant
ADRO: 14.68 (+0.15), PFE: 34.28 (+0.47), LLY: 80.87 (+0.99), BMY: 55.93 (+0.37), EGRX: 66.17 (+1.22), GSK: 43.21 (+0.15), SNTA: 0.34 (+0.07), MRK: 62.70 (+0.76), AVEO: 0.87 (unch), TCON: 5.95 (+0.31), NVS: 81.52 (+0.46), FPRX: 52.82 (+0.81)
Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 14.73 (-0.09), PFE: 34.28 (+0.47), AKAO: 4.16 (-0.05), GLYC: 7.40 (-0.06), GSK: 43.21 (+0.15), APHB: 1.51 (-0.03), SRPT: 56.22 (+0.49), ACH: 9.19 (+0.13), AZN: 33.75 (+0.10)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.64 (+0.02), GALT: 2.60 (+0.68), LLY: 80.87 (+0.99), BMY: 55.93 (+0.37), GLPG: 67.59 (+0.16), GILD: 81.70 (-0.08), IBIO: 0.55 (-0.01), TEVA: 50.48 (+0.12), FGEN: 21.83 (+0.24), CELGZ: 1.25 (+0.05)
Global Idiopathic Pulmonary Fibrosis Therapeutics Pipeline Review 2015
M2 - Wed Jan 06, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/63sldq/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - List of Tables - List of Figures - Introduction - Idiopathic Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview - Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis - Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies - Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Pipeline Products Glance - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Idiopathic Pulmonary Fibrosis - Products under Development by Companies - Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - GenKyoTex S.A. - Gilead Sciences, Inc. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - MedImmune, LLC - Moerae Matrix, Inc. - MorphoSys AG - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. - Respira Therapeutics, Inc. - Rhizen Pharmaceuticals SA - Ribomic Inc. - Sanofi - Teva Pharmaceutical Industries Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/63sldq/idiopathic
BMY: 55.93 (+0.37), GLPG: 67.59 (+0.16), GILD: 81.70 (-0.08), CGEN: 6.70 (+0.04), IBIO: 0.55 (-0.01), TEVA: 50.48 (+0.12), FGEN: 21.83 (+0.24), CELGZ: 1.25 (+0.05)
Aeolus Announces Fiscal Year 2015 Financial Results
Marketwired - Fri Dec 18, 4:09PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today financial results for the three months and twelve months ended September 30, 2015.
Epilepsy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfmq9k/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - Alexza Pharmaceuticals, Inc. - Allergan Plc - Anavex Life Sciences Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Biscayne Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - Epirus Biopharmaceuticals, Inc. - Glialogix, Inc. - GW Pharmaceuticals Plc - H. Lundbeck A/S - Hyundai Pharmaceutical Co., Ltd. - INSYS Therapeutics, Inc. - Iproteos S.L. - Others (30) For more information visit http://www.researchandmarkets.com/research/rfmq9k/epilepsy
AGN: 238.41 (-0.26), INSY: 13.27 (-0.48), CPRX: 1.09 (+0.03), AVXL: 2.61 (-0.03), ACOR: 27.07 (+0.71), CNCE: 10.42 (-0.11)
Aeolus Pharmaceuticals to Present at Aegis Growth Conference on September 22, 2016
Marketwired - Wed Aug 31, 8:09AM CDT
MISSION VIEJO, CA--(Marketwired - August 31, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today that it will be presenting at the 2016 Aegis Growth Conference on Thursday, September 22nd at 9:00AM PDT / 12 Noon EDT at the Encore at Wynn in Las Vegas. David C. Cavalier, Chairman and Chief Financial Officer will be giving the presentation and meeting with investors.
Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results
Marketwired - Mon Aug 15, 3:29PM CDT
MISSION VIEJO, CA--(Marketwired - August 15, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today financial results for the nine months ended June 30, 2016.
Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference
Marketwire Canada - Mon May 23, 7:01AM CDT
MISSION VIEJO, CA--(Marketwired - May 23, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today that it will be presenting at the 6th annual LD Micro Invitational on Tuesday, June 7th at 9:00AM PDT / 12 Noon EDT at the Luxe Sunset Boulevard Hotel in Los Angeles. David C. Cavalier, Chairman and Chief Financial Officer will be giving the presentation and meeting with investors.
CORRECTION - Aeolus Announces Second Quarter Fiscal Year 2016 Financial Results and Investor Update Call
Marketwire Canada - Mon May 16, 7:43AM CDT
MISSION VIEJO, CA --(Marketwired - May 16, 2016) - In the news release issued earlier today by Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), we are advised by the company that the headline of the release should read "Aeolus Announces Second Quarter Fiscal Year 2016 Financial Results and Investor Update Call" rather than "Aeolus Announces First Quarter Fiscal Year 2016 Financial Results and Investor Update Call" as originally issued. Complete corrected text follows.
Aeolus Announces First Quarter Fiscal Year 2016 Financial Results and Investor Update Call
Marketwire Canada - Mon May 16, 7:02AM CDT
MISSION VIEJO, CA--(Marketwired - May 16, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today financial results for the three months ended March 31, 2016. The Company also announced a conference call to update investors on its development programs, including its partnership with the Biomedical Advanced Research and Development Authority ("BARDA"
for the development of AEOL-10150 ("10150" as treatment for the pulmonary and delayed effects of acute radiation exposure ("Lung-ARS" . European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114
Marketwired - Mon Apr 18, 7:02AM CDT
Aeolus Pharmaceuticals (OTCQB: AOLS)
Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 238.41 (-0.26), AVXL: 2.61 (-0.03), ACOR: 27.07 (+0.71), BCLI: 2.42 (-0.10), FOLD: 7.94 (+0.05)
Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malignant Mesothelioma Overview - Therapeutics Development - Pipeline Products for Malignant Mesothelioma - Overview - Pipeline Products for Malignant Mesothelioma - Comparative Analysis - Malignant Mesothelioma - Therapeutics under Development by Companies - Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes - Malignant Mesothelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malignant Mesothelioma - Products under Development by Companies - Malignant Mesothelioma - Products under Investigation by Universities/Institutes - Malignant Mesothelioma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Berg LLC - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Synta Pharmaceuticals Corp. - Targovax AS - TRACON Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2dt2rm/malignant
ADRO: 14.68 (+0.15), PFE: 34.28 (+0.47), LLY: 80.87 (+0.99), BMY: 55.93 (+0.37), EGRX: 66.17 (+1.22), GSK: 43.21 (+0.15), SNTA: 0.34 (+0.07), MRK: 62.70 (+0.76), AVEO: 0.87 (unch), TCON: 5.95 (+0.31), NVS: 81.52 (+0.46), FPRX: 52.82 (+0.81)
Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 14.73 (-0.09), PFE: 34.28 (+0.47), AKAO: 4.16 (-0.05), GLYC: 7.40 (-0.06), GSK: 43.21 (+0.15), APHB: 1.51 (-0.03), SRPT: 56.22 (+0.49), ACH: 9.19 (+0.13), AZN: 33.75 (+0.10)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.64 (+0.02), GALT: 2.60 (+0.68), LLY: 80.87 (+0.99), BMY: 55.93 (+0.37), GLPG: 67.59 (+0.16), GILD: 81.70 (-0.08), IBIO: 0.55 (-0.01), TEVA: 50.48 (+0.12), FGEN: 21.83 (+0.24), CELGZ: 1.25 (+0.05)
Global Idiopathic Pulmonary Fibrosis Therapeutics Pipeline Review 2015
M2 - Wed Jan 06, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/63sldq/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - List of Tables - List of Figures - Introduction - Idiopathic Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview - Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis - Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies - Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Pipeline Products Glance - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Idiopathic Pulmonary Fibrosis - Products under Development by Companies - Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - GenKyoTex S.A. - Gilead Sciences, Inc. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - MedImmune, LLC - Moerae Matrix, Inc. - MorphoSys AG - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. - Respira Therapeutics, Inc. - Rhizen Pharmaceuticals SA - Ribomic Inc. - Sanofi - Teva Pharmaceutical Industries Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/63sldq/idiopathic
BMY: 55.93 (+0.37), GLPG: 67.59 (+0.16), GILD: 81.70 (-0.08), CGEN: 6.70 (+0.04), IBIO: 0.55 (-0.01), TEVA: 50.48 (+0.12), FGEN: 21.83 (+0.24), CELGZ: 1.25 (+0.05)
Aeolus Announces Fiscal Year 2015 Financial Results
Marketwired - Fri Dec 18, 4:09PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today financial results for the three months and twelve months ended September 30, 2015.
Epilepsy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfmq9k/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - Alexza Pharmaceuticals, Inc. - Allergan Plc - Anavex Life Sciences Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Biscayne Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - Epirus Biopharmaceuticals, Inc. - Glialogix, Inc. - GW Pharmaceuticals Plc - H. Lundbeck A/S - Hyundai Pharmaceutical Co., Ltd. - INSYS Therapeutics, Inc. - Iproteos S.L. - Others (30) For more information visit http://www.researchandmarkets.com/research/rfmq9k/epilepsy
AGN: 238.41 (-0.26), INSY: 13.27 (-0.48), CPRX: 1.09 (+0.03), AVXL: 2.61 (-0.03), ACOR: 27.07 (+0.71), CNCE: 10.42 (-0.11)
(0)
(0)Scroll down for more posts ▼